Evidence map›Paper›PMID 34187263›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2021

Molecular design, synthesis and

Mona M Abdel-Atty, Nahla A Farag, Rabah A T Serya, Khaled A M Abouzid, Samar Mowafy

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Mona M Abdel-AttyPharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Nahla A FaragPharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Rabah A T SeryaPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Khaled A M AbouzidPharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Samar MowafyPharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, Cairo, Egypt.
Misr International University · EGAin Shams University · EGUniversity of Sadat City · EGUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of thieno[2,3-

Indexed as

Antineoplastic AgentsCell Line, TumorDrug DesignDrug Screening Assays, AntitumorErbB ReceptorsHistone Deacetylase InhibitorsHumansHydroxamic AcidsIn Vitro TechniquesMolecular Docking SimulationPyrimidinesVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsEGFR protein, humanErbB ReceptorsHistone Deacetylase InhibitorsHydroxamic AcidsKDR protein, humanPyrimidinesthienopyrimidineVascular Endothelial Growth Factor Receptor-2Thieno[2,3-d]pyrimidine; hydroxamic acid derivatives; chimeric HDAC-kinase inhibitors; multitarget therapy lead; ADMET study

Identifiers

PMID34187263
PMCPMC8253220
OpenAlexW3175523011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.